Valneva SE (VALN)
| Market Cap | 1.41B |
| Revenue (ttm) | 134.54M |
| Net Income (ttm) | -78.53M |
| Shares Out | 48.94M |
| EPS (ttm) | -1.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $28.87 |
| Previous Close | $28.48 |
| Change ($) | 0.39 |
| Change (%) | 1.37% |
| Day's Open | 28.20 |
| Day's Range | 27.88 - 29.11 |
| Day's Volume | 5,923 |
| 52-Week Range | 26.56 - 30.47 |
Saint-Herblain (France) – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines...
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines...
Saint-Herblain (France), May 5, 2021 – Valneva SE (the “Company”), a specialty vaccine company focused on the development and commercialization of...
Valneva SE (the “Company”), a specialty vaccine company focused on the development and commercialization of...
Valneva SE has filed to go public with an IPO on the NASDAQ.
Valneva on Tuesday reported positive results for its COVID-19 vaccine in early stage clinical trials and said it planned to launch a Phase Three trial this month.
About VALN
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. We take a highly specialized and targeted approach to vaccine development, beginning with the identification of deadly and debilitating infectious diseases that lack a prophylactic vaccine solution and for which there are limited therapeutic treatment options. We then apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities... [Read more...]
| Industry Biological Products | IPO Date May 6, 2021 |
| CEO Thomas Lingelbach | Employees 579 |
| Stock Exchange NASDAQ | Ticker Symbol VALN |
Financial Performance
In 2020, Valneva's revenue was 110.32 million, a decrease of -12.58% compared to the previous year's 126.20 million. Losses were -64.39 million, 3,592.3% more than in 2019.